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Resumo
O cancro renal ou carcinoma de ce´lulas renais (renal cell carcinoma - RCC) e´ um grupo
comum de doenc¸as resistentes a quimioterapia. E´ um dos tipos de cancro mais letal no
sistema urina´rio, sendo a taxa de sobreviveˆncia para os pacientes com RCC metasta´tico
de menos de 10% apo´s cinco anos de diagno´stico.
Com base nas suas caracterı´sticas gene´ticas e histolo´gicas, no seu feno´tipo clı´nico e
diferentes respostas a` terapia, os RCCs podem ser subdivididos em va´rios tipos, sendo
um dos mais comuns o de ce´lulas claras RCC ( clear cell renal cell carcinoma - ccRCC);
correspondendo a mais de 80% dos casos de RCC.
Uma das caracterı´sticas do ccRCC, bem como de outros tipos de cancro, e´ a metaboliza-
c¸a˜o da glucose atrave´s da glico´lise seguido pela produc¸a˜o de lactato, processo primeira-
mente descrito por Warburg - ” efeito de Warburg ”. Este efeito ocorre em oposic¸a˜o
a` normal glico´lise seguida de fosforilac¸a˜o oxidativa mitocondrial, a fim de produzir o
adenosina trifosfato (ATP).
Esta caracterı´stica deriva principalmente do gene von Hippel-Lindau (VHL) inactivo,
contudo este apenas apresenta mutac¸o˜es que podem inactivar a sua func¸a˜o em apenas
52% das amostras de ccRCC. Esta mutac¸a˜o podera´ na˜o ser suficiente para explicar este
carcinoma e que mais estudos sa˜o necessa´rios a fim de entendeˆ-la. Um papel importante
neste cancro tambe´m tem sido atribuı´do a` regulac¸a˜o epigene´tica, bem como a microRNAs
desregulados.
Desde o inı´cio do se´culo XXI, va´rios projectos a nı´vel global teˆm permitido descartar
a ideia de que o genoma humano e´ principalmente ” lixo” e para isso tambe´m contribuiu
o desenvolvimento de tecnologias de sequenciac¸a˜o de nova gerac¸a˜o (next generation se-
quencing – NGS).
Algumas destas tecnologias sa˜o a Roche 454, Illumina / Solexa e tecnologias ABI-
Solid que permitem sequenciar todo o genoma/ transcriptoma de uma so´ vez. De modo
a ocorrer esta sequenciac¸a˜o e´ necessa´ria uma fragmentac¸a˜o do material gene´tico; uma
reacc¸a˜o em cadeia da polimerase (polimerase chain reaction - PCR) em paralelo e determi-
nac¸a˜o da sequeˆncia atrave´s de fluoresceˆncia. Nos u´ltimos anos, surgiram tecnologias de
sequenciac¸a˜o de terceira gerac¸a˜o (como PacBio e Helicos) capazes de definir a sequeˆncia
utilizando mole´culas individuais de DNA, sem necessidade de reacc¸o˜es de PCR.
Actualmente, grande parte das tecnologias disponı´veis apresentam va´rias vantagens
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e limitac¸o˜es, sendo o mais importante na escolha de uma destas o equilı´brio entre os
objectivos e o orc¸amento disponı´vel.
Uma das te´cnicas que tira partido destas tecnologias e´ a sequenciac¸a˜o de RNA (RNA-
seq). Esta te´cnica, utiliza tecnologias de sequenciac¸a˜o de nova gerac¸a˜o, a fim de analisar
todas as mole´culas de a´cido ribonucleico (ribonucleic acid - RNA) de uma ou mais ce´lulas
– transcriptoma. A ana´lise deste tipo de dados permite fornecer informac¸o˜es a nı´vel de
sequeˆncia, bem como sobre nı´veis de transcric¸a˜o, facilitando o desenvolvimento de novas
terapeˆuticas e interpretac¸a˜o de dados experimentais.
Esta revoluc¸a˜o tecnolo´gica levou ao reconhecimento de que o transcriptoma na˜o e´
apenas constituı´do por transcritos codificantes de proteı´nas, mas tambe´m por um elevado
nu´mero de transcritos na˜o codificantes. Transcritos estes que esta˜o a ser gerados a partir
de regio˜es que se acreditava ser ”desertos”. A transcric¸a˜o generalizada das regio˜es na˜o
codificantes pode estar na origem de mole´culas funcionais. Torna-se assim evidente que
existe uma necessidade de ter em conta elementos na˜o codificantes, ao serem realizados
estudos de associac¸a˜o ao nı´vel do genoma.
Os transcritos na˜o codificantes (non coding RNA - ncRNA) esta˜o associados a va´rias
func¸o˜es a nı´vel celular e pedem ser dividos em va´rias categorias, de acordo com o seu
tamanho e localizac¸a˜o relativa a genes codificantes de proteı´na. Um dos grupos de ncRNA
sa˜o os longos transcritos na˜o codificantes interge´nicos (long non coding intergenic RNA
– lincRNA), que apresentam um tamanho superior a 200 nucleo´tidos e na˜o apresentam
nenhuma sobreposic¸a˜o com outros genes anotados.
Estes na˜o apresentam nenhuma caracterı´stica especı´fica sendo que podem ser tran-
scritos pela mesma maquinaria que permite a transcric¸a˜o de genes codificantes de proteı´nas.
Normalmente apresentam cerca de 2 a 3 exo˜es e o nı´vel de expressa˜o e´ menos elevado
que o dos genes codificantes. O papel biolo´gico da maioria destes ainda e´, em grande
parte desconhecido, contudo alguns deles teˆm sido associados a va´rios tipos de cancro.
Apesar da quantidade de estudos feitos em ccRCC e da quantidade de mutac¸o˜es iden-
tificadas, ainda na˜o e´ possı´vel compreender este subtipo de carcinoma renal. Assim,
decidiu-se explorar o perfil de expressa˜o de lincRNAs em ccRCC e quantificar diferenc¸a
na expressa˜o destes, comparando amostras normais versus a amostras de tumor de 62 pa-
cientes com ccRCC. Para isso, e´ necessa´rio construir o transcriptoma base do ccRCC para
a descoberta de potenciais novos lincRNAs; analisar a expressa˜o diferencial de lincRNA
e mostrar sua correlac¸a˜o com genes que codificam proteı´nas. Foi enta˜o utilizada uma
ana´lise computacional de dados de RNA-seq de 62 amostras de pacientes ccRCC (pares
de amostra tumoral e normal).
Primeirament foi construido um cata´logo com lincRNAs humanos, utilizadando anotac¸o˜es
de lincRNA de va´rias bases de dados (Ensembl, Gencode, Vega, Lncipedia, UCSC, do
Instituto Broad, Noncode e dados publicados por Zhipeng e Adelson). A falta de cor-
respondeˆncia entre as diferentes bases de dados, aumentou o grau de complexidade do
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processo, contudo no final foi obtido um cata´logo de 38 134 lincRNAs humanos.
De seguida, foi reconstruı´do o transcriptoma do ccRCC para usar como base para nova
descoberta de lincRNAs. A caracterizac¸a˜o das 62 amostras de pacientes ccRCC (tumor e
normal combinado) revelou 5549 potenciais novos linRNAs. A ana´lise diferencial entre
as amostras de cancro e tecido normal permitiu a identificac¸a˜o de 2129 genes diferencial-
mente expressos ( entre os quais 239 lincRNA e 105 potencias novos lincRNAs).
Devido aos seus baixos nı´veis de expressa˜o, para muitos dos lincRNAS o teste es-
tatı´stico na˜o foi sequer efectuado. Facto pelo qual, o u´ltimo passo envolveu uma ana´lise
que tem em conta a relac¸a˜o entre os transcritos, independentemente da sua expressa˜o
diferencial. Foi realizada uma ana´lise de correlac¸a˜o ge´nica em rede (gene correlation
network analysis), permitindo encontrar genes altamente correlacionados entre si e o tipo
de amostra - tumor / normal. E´ de realc¸ar o lincRNA PVT1, que foi previamente as-
sociado a outros tipos de cancro e tem uma elevada expressaa˜o em amostras de tumor
ccRCC. Pacientes com elevada expressaa˜o relativa deste lincRNA nas amostras normais,
teˆm uma probabilidade inferior de sobreviveˆncia comparativamente aos que apresentam
uma menor expressa˜o relativa.
No final, esta ana´lise permitiu a dar os primeiros na compreensa˜o a importaˆncia dos
lincRNAs no ccRCC.
Palavras chave: lincRNA, ccRCC, RNA-seq, diferencialmente expresso, FPKM,
rede de correlac¸a˜o ge´nica.
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Abstract
Kidney cancer or renal cell carcinoma (RCC) is a common group of chemotherapy re-
sistant diseases, and one of the most lethal type of cancer in the urinary system, being
the survival rate for patients suffering from metastatic RCC is less than 10% survive five
years subsequent to diagnosis.
Based on their genetic characteristics, histological features, clinical phenotype and
different responses to therapy, RCCs can be subdivided in several subtypes, one of the
most common being clear cell RCC (ccRCC) accounting for more than 80% of RCC
cases. ccRCC is usually characterized with an inactive von Hippel–Lindau (VHL) gene,
the VHL gene mutations that can inactivate were observed only in 52% samples, which
may indicate that this mutation is not sufficient to explain this carcinoma and that more
studies are necessary in order to understand it. An important role for epigenetic regulation
has also been suggested for ccRCC, as well for deregulated microRNAs.
The development of next generation sequencing technologies (NGS) made possible
for a bigger number of transcriptomes to be analysed. This allowed to acknowledge that
a transcriptome is not only constitute by protein-coding transcripts but also by a high
number of non-coding transcripts. This transcripts are being transcribed from regions
previously thought to be “deserts”. This widespread transcription of non-coding regions
may be in the origin of functional molecules, making apparent that there is a need to take
into account non-coding elements when genome wide association studies are done.
Non-coding RNA (ncRNA) are associated with plenty of functions and one group of
ncRNA - long intergenic ncRNA, which have no overlap other annotated genes, have been
associated with several other cancers.
Despite the amount of studies made in ccRCC and the amount of identified mutations
it is still not possible to comprehend this subtype of renal carcinoma. Thus, we decided
to explore the long intergenic non-coding RNA (lincRNA) profile in ccRCC and quantify
difference in gene expression when comparing the normal versus the tumor samples.
For that is necessary to assemble the ccRCC transcriptome as base for potentially new
lincRNA discovery, analyse differential lincRNA expression and show their correlation
with protein coding genes.
In order to achieve that, a computational analysis of RNA-seq pair-end data of 62
ccRCC patient samples (tumor and matched normal) was used.
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In order to accomplish these objectives, a human lincRNA catalog, with lincRNA
annotations from several databases (Ensembl, Gencode, Vega, Lncipedia, UCSC, Broad
Institute, Noncode and Zhipeng and Adelson published data) had to be constructed. The
main preoccupation was to have the most complete tool/resource for assessing lincRNA
expression. For that, 8 different databases with lincRNA annotations were merged in
order to obtain a unified human catalogue of 38 134 lincRNAs.
To uncover the lincRNA profile in ccRCC, the transcriptome composition of 62 ccRCC
patient samples (tumor and matched normal) was assessed. Available bioinformatic tools
were used and made possible the identification of 5549 potentially new lincRNA and
determine 2129 differentially expressed genes (239 lincRNA and 105 potentially new lin-
cRNAs).
In order to proceed with an analysis that takes into account the relationship between
the transcripts, independently of their differential expression, a weighted gene correlation
network analysis followed. This analysis allowed to find highly co-expressed/correlated
genes as well as genes highly correlated with sample type – tumor/normal sample, leading
to uncover PVT1 lincRNA. This lincRNA was already associated with other cancers and
has an expression highly upregulated in ccRCC tumor samples. Patients with relative high
expression of this lincRNA in normal samples also show poor survival chances.
In the end, this analysis allowed to give the first steps in order to understand the
lincRNAs importance in ccRCC.
Key words: lincRNA, ccRCC, RNA-seq, differentially expressed, FPKM, gene cor-
relation network.
xii
Contents
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xv
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xvii
List of Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xix
1 Introduction 1
1.1 Gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 High throughput sequencing . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2.1 RNA-seq . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.3 Long intergenic non-coding RNA . . . . . . . . . . . . . . . . . . . . . 6
1.4 Clear cell renal cell carcinoma . . . . . . . . . . . . . . . . . . . . . . . 9
1.4.1 ccRCC characteristics . . . . . . . . . . . . . . . . . . . . . . . 10
1.4.2 Therapies used in ccRCC . . . . . . . . . . . . . . . . . . . . . . 12
1.5 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2 Human LincRNA catalog 15
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.2 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.2.1 LincRNA obtainment . . . . . . . . . . . . . . . . . . . . . . . . 16
2.2.2 Isoform merge . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.2.3 All databases merge . . . . . . . . . . . . . . . . . . . . . . . . 16
2.3 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.3.1 LincRNA obtainment . . . . . . . . . . . . . . . . . . . . . . . . 18
2.3.2 Isoform merge . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.3.3 All databases merge . . . . . . . . . . . . . . . . . . . . . . . . 21
3 LincRNA profile in clear cell renal cell carcinoma 25
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.1.1 Regulatory roles of lincRNA in cancer . . . . . . . . . . . . . . . 25
3.1.2 Diagnostic and potential therapeutics of lincRNAs in cancer . . . 26
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.2.1 Data set . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.2.2 Transcriptome composition . . . . . . . . . . . . . . . . . . . . . 28
xiii
3.2.3 Gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.2.4 Enrichment analysis . . . . . . . . . . . . . . . . . . . . . . . . 30
3.2.5 Weighted gene correlation network analysis . . . . . . . . . . . . 30
3.3 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.3.1 Transcriptome composition . . . . . . . . . . . . . . . . . . . . . 33
3.3.2 Gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.3.3 Weighted gene correlation network analysis . . . . . . . . . . . . 38
4 Final Remarks and Future Perspectives 45
Bibliography 47
Appendix 53
LincRNA profile in ccRCC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
xiv
List of Tables
1.1 Technical specifications of NGS technologies . . . . . . . . . . . . . . . 4
3.1 LincRNAs associated with cancer . . . . . . . . . . . . . . . . . . . . . 25
3.2 Characteristics of the 62 ccRCC patients . . . . . . . . . . . . . . . . . . 27
3.3 Commands used for transcriptome composition assessment . . . . . . . . 28
3.4 Trasncriptome composition . . . . . . . . . . . . . . . . . . . . . . . . . 33
A.1.1TCGA samples . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
xv

List of Figures
1.1 Overview of gene transcription . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Evolution of DNA sequencing technologies . . . . . . . . . . . . . . . . 3
1.3 RNA-seq process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.4 Number of lincRNA results in PubMed . . . . . . . . . . . . . . . . . . 7
1.5 Generalized mechanisms of lincRNA . . . . . . . . . . . . . . . . . . . . 9
1.6 Typical presentation of ccRCC . . . . . . . . . . . . . . . . . . . . . . . 11
1.7 Molecular targets of treatments for ccRCC . . . . . . . . . . . . . . . . . 13
2.1 LincRNA annotation process . . . . . . . . . . . . . . . . . . . . . . . . 17
2.2 Subtracted lnc/lincRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.3 LincRNA information available in databases . . . . . . . . . . . . . . . . 19
2.4 Isoform merge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.5 All database merge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.6 Comparison lincRNA annotations databases . . . . . . . . . . . . . . . . 23
3.1 LincRNAs associated mechanisms of action . . . . . . . . . . . . . . . . 26
3.2 Transcriptome composition . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.3 FPKM distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.4 FPKM unbiased clustering analysis . . . . . . . . . . . . . . . . . . . . . 35
3.5 Differentially expressed . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.6 Differentially expressed gene enrichment . . . . . . . . . . . . . . . . . 37
3.7 WGCNA network construction . . . . . . . . . . . . . . . . . . . . . . . 39
3.8 WGCNA modules analysis . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.9 Heatmap of top 200 genes more correlated with sample type . . . . . . . 42
3.10 PVT1 lincRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
xvii

List of Abbreviations
ATP adenosine triphosphate
bp Base pair(s)
ccRCC clear cell Renal Cell Carcinoma
cDNA complementary DNA
DNA Deoxyribonucleic acid
FDR false discovery rate
FPKM fragments per kilobase of exon per million fragments
Glu1 glucose transporter 1
H3K36me3 trimethylation of lysine 36 in histone H3
H3K4me3 trimethylation of lysine 4 in histone H3
HIF-α hypoxia-inducible factor subunit α
HIF-β hypoxia-inducible factor subunit -β
HRE hypoxia response element
LDH lactate dehydrogenase
lincRNA long intergenic non-coding RNA
lncRNA long non-coding RNA
MCT4 monocarboxilate transporter 4
mRNA messenger RNA
mTOR mammalian target of rapamycin
NADPH nicotinamide adenine dinucleotide phosphate
xix
ncRNA non-coding RNA
NGS Next-Generation Sequencing
nt nucleotide(s)
PCA Principal Component Analysis
PCR Polymerase Chain Reaction
PDK-1 pyruvate dehydrogenase kinase 1
PPP pentose phosphate pathway
pre-mRNA pre-messenger RNA
RCC Renal Cell Carcinoma
RNA-seq RNA sequencing
RNA Ribonucleic acid
rRNA ribossomal RNA
TCGA The Cancer Genome Atlas
VEGF vascular endothelial growth factor
VHL von Hippel–Lindau tumor suppressor gene
WGCNA Weighted gene correlation network analysis
xx
Chapter 1
Introduction
From the beginning of the XXI century projects like ENCODE (Encyclopedia Of DNA
Elements) (The ENCODE Project Consortium, 2004) allowed to dismiss the view that
the human genome is mostly “junk DNA”, hence 80% of the genome contains elements
linked to biochemical functions (Ecker et al., 2012), bringing to light, among other ele-
ments, transcripts that have little protein-coding capacity (Gingeras, 2007) – non-coding
ribonucleic acid (other than ribossomic RNA or transfer RNA), but that may have func-
tion. Together with this came the development of high throughput sequencing technolo-
gies, and the world entered in a new genomic era that brought huge impacts on genetic
applications like metagenomics, comparative genomics, high throughput polymorphism
detection, analysis of small RNAs, mutation screening, transcriptome profiling, methyla-
tion profiling, and chromatin remodeling (Yadav et al., 2014) .
1.1 Gene expression
According to HUGO’s gene Nomenclature Committee (Wain et al., 2002), a gene is de-
fined as a deoxyribonucleic acid (DNA) segment that contributes to phenotype/function
and in the absence of demonstrated function it may be characterized by sequence, tran-
scription or homology.
The information present in a gene is transformed into a functional gene product,
being this a protein or a functional ribonucleic acid (RNA), through gene expres-
sion. If the functional gene product is a protein, DNA needs to be transcribed to a pre-
messenger RNA (pre-mRNA) by RNA polymerase, processed into a mature messenger
RNA (mRNA), translated into a polypeptide in the cytoplasm, folded into proper three-
dimensional structure. On the contrary, if the final product is a functional RNA, DNA is
transcribed into a non-coding RNA (ncRNA) by RNA polymerase and processed into a
functional RNA.
In the human genome, gene transcription can be processed by three different nuclear
RNA polymerases and a forth that is present in the mitochondria. The nuclear poly-
1
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merases have distinct functions and use different promoters. Protein coding genes are
transcribed by RNA polymerase II whereas genes that result into a functional RNA may
be transcribed by RNA polymerase I, II or III, depending on RNA type (Strachan and
Read, 2010).
Using RNA-sequencing (RNA-seq) technology, Djebali and colleagues (Djebali et al.,
2012) report evidence that 75% of the human genome can be transcribed at some
point, as well an increased overlap of genic regions due to transcripts being synthesized
from both strands, forcing a review of the actual gene concept and the minimum unit of
heredity, and bringing more plausibility to the concept that it is possible for a gene to
transcribe for multiple different transcripts (coding and non-coding) and have multiple
regulatory regions (Gingeras, 2007).
Figure 1.1: Global view of what happens in order to gene transcription occur and several ele-
ments that can intervene in this process. Here is possible to observe that in order for a gene to
be transcribed, is necessary a decondensation of the chromosome (through the action of DNA
demethylations and histone modification enzymes) in order for the DNA strand to be accessible
for the transcriptional machinery. Several others factors, as chromatin interactions, transcription
factors binding sites or long range regulatory elements, among others, can also induce/repress the
transcription of a gene. Image adapted from Ecker et al. 2012
In this new genomic era it becomes clearer that gene transcription is a well coordi-
nate choreography between DNA structure, sequence and regulatory elements. Chemical
modification of histones, DNA methylation state can influence the transcription of DNA
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(Ecker et al., 2012) as well as other regulatory elements (desoxirribonuclease I, binding
sites, transcription factor binding site, long range regulatory binding sites, DNA binding
proteins, RNA molecules, etc). In Figure 1.1 it is possible to observe a general view of
what happens in order for a gene to be transcribed into a protein-coding or a non-coding
transcript.
1.2 High throughput sequencing
With the DNA double helix structure identification by Watson and Crick in 1953, the
world started a new journey in order to discover all genome’s particularities. Sanger
et all (Sanger et al., 1977), developed the di-deoxi chain termination method in 1977,
which allowed to determine DNA sequence of a certain region; method broadly used by
scientists until a decade ago. Only in the 2000’s started to appear technologies capable to
sequence all the genome at once. Nowadays, a lot of technologies are available, presenting
all advantages and limitations; being the most important when choosing one of them, the
balance between goals and the available money. In Figure 1.2 it is possible to observe the
evolution of DNA sequencing technologies along the years.
Figure 1.2: Evolution of DNA sequencing technologies. Adapted from Gupta and Gupta (2014)
Roche 454, Illumina/Solexa, and ABI-SOLiD technologies are called next-generation
sequencing (NGS) or second generation sequencing. In these technologies, all genome/
transcriptome is fragmented, and the resulting fragments are sequenced at the same time
– parallel sequencing, still existing the need to amplify them by Polymerase Chain Re-
action (PCR) reaction before sequence determination, which is achieved by fluorescence
detection. Third generation sequencing (like PacBio and Helicos) is able to define the
DNA sequence using single DNA molecules, without need of PCR reactions. IonTorrent
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technology is not a single molecule sequencing technique, but neither a second generation
hence the determination of sequence does not depend on fluorescence bun on hydrogen
ion detection when nucleotides are incorporate into a growing DNA template (Gupta and
Gupta, 2014). Some of the technical specifications of these NGS technologies can be
consulted in Table 1.1.
Other technologies (Gupta and Gupta, 2014) are being developed, using other type of
chemistries when sequencing, but the final goal is to make sequencing cheaper and avail-
able for everyone. The next generations sequencing may have many applications (Gupta
and Gupta, 2014), as whole genome sequencing/re-sequencing, transcriptome sequencing
(RNA-seq), sequence of DNA that interacts with proteins, .etc.
Table 1.1: Technical specifications of NGS technologies. Adapted from Gupta and Gupta (2014);
Liu et al. (2012); Quail et al. (2012); www.allseq.com - accessed on 11 August 2014.
454 Illumina(HiSeq 2000)
Pac Bio
(RS II)
Ion Torrent
(PMG 318) SoLiD
Chemestry Pyrosequencing Sequencing bysynthesis
Real time
sequencing Proton detection
Sequencing by
ligation
Machine price ∼$500k ∼$690k ∼$700k ∼$50k ∼$495k
Sequencing cost per
million bases $10 $0.07 $1 $2 $0.13
Read length up to 1000bp ∼1500bp 3000∼15 000 bp up to 400b ∼85bp
Observed error rate ∼0.1% 0.26% 12.86% 1.71% 0.06%
Time per run 23 hours 3-10 days 3 hours 4-7 hours 8 days
Total output per run 700 Mb 600 Gb ∼300 Mb 1Gb 120Gb
Advantage Fast and largeread length
High
throughput
No PCR nedeed;
long reads
Fast High accuracy
Disadvantage
Hing error
introduction
in homopolymers
Short read High error rate
Short reads
and low
amount of
output data
Short reads
and low
amount of
output data
1.2.1 RNA-seq
RNA sequencing (RNA-seq) uses next generation sequencing technologies in order to
analyse all ribonucleic acid (RNA) molecules of one or more cells – transcriptome, pro-
viding information about their sequence and transcription level, facilitating thus the de-
sign of therapeutics and experimental data interpretation (Chu and Corey, 2012), as well
as revising previously annotated genes (Nagalakshmi et al., 2010).
The RNA-seq process includes three main steps in order to obtain biological in-
sights from the experiment, (1) library preparation, (2) sequencing and (3) bioinfor-
Chapter 1. Introduction 5
matic/computational biology analysis of the data, as observed in Figure 1.3.
LIBRARY PREPARATION 
• RNA sample 
• rRNA depletion /mRNA 
enrichment 
• Fragmentation 
• Reverse transcription 
• Adapter ligation 
SEQUENCING 
• Clonal amplification 
• Sequencing 
• Raw image data 
• Short sequences 
BIOINFORMATICS/ COMPUTATIONAL 
BIOLOGY ANALYSIS 
• Quality assessment  –  fastQC  
• Map to reference – TopHat/Bowtie 
• Transcriptome map 
New gene isoforms identification 
Cufflinks 
 
Non-code RNA identification  
Cufflinks 
Novel transcript 
detection 
Copy number 
variation identification 
Single nucleotide 
polymorphism identification 
Read count 
HtSeq, Cufflinks 
 
Normalization 
Cufflinks, EDAseq* 
 
Diferrential expression analysis 
Cufflinks, DESseq*, edgeR* 
 
Functional analysis 
DAVID, Kegg  pathways 
Gene expression 
analysis 
TopHat-fusion, deFuse 
Gene fusion detection 
 Miso, MATS e Cufflinks 
 
Alternative splicing 
identification 
Figure 1.3: RNA-seq process includes three main steps: (1) library preparation, (2) sequencing and
(3) bioinformatic/computational biology analysis of the data. Each one of the steps have different
sub-steps that need to be followd in order to complete the experiment with success. In the third
step are depicted some of the analysis that can be done with this kind of data; as well as some of
the open source software available, written in italic and the ones with ”*” are R packages that can
be installed and do the desired analysis. Adapted from Qian et al. (2014); Atak et al. (2013)
The first step of the process - library preparation, involves the conversion of the
cellular RNA molecules (total RNA, mRNA or other sub-population of RNA molecules)
into molecules that can be sequenced. As ribosomal RNA (rRNA) is one of the most
abundant RNA form the cell, these needs to be depleted in order to ensure that transcripts
that are rare to be sequenced with a proper depth. Next follows RNA fragmentation
into smaller fragments suitable for sequencing, conversion of the RNA fragments into
complementary DNA (cDNA), by reverse transcriptase enzyme action, and finally the
attachment of adaptors that allow the amplification and sequencing step (Chu and Corey,
2012).
When creating the library, it is possible to retain information of transcript orientation,
although more complicated; and during the sequencing, the fragments present in the
library can be sequenced from one – single-end sequencing, or both ends – paired-end
sequencing. The advantage of using paired-end sequencing is that the distance between
each paired-end is known, which makes the mapping, against reference annotation, of
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reads among repetitive regions more precise (Illumina Inc., 2013). Depending on the
used technology, the resulting short reads can cave between 30 and 400 base pairs (bp) of
length (Wang et al., 2009; Nagalakshmi et al., 2010).
The usual analysis work flow of RNA-seq data (Mutz et al., 2013), if a genome/transcriptome
reference is available, consists in:
1. Converting row image data into read sequences;
2. Map read sequences against the reference, in order to reconstruct the transcriptome;
3. Count reads and calculate gene expression and normalizing by region length and
library size (RPKMs);
4. Determine differential gene expression using statistical tests.
Several other approaches can be used in order to achieve more specific goals and
several tools have been developed in order to permit that (Figure 1.3), most of them being
available for free. RNA-seq can offer several advantages (Wang et al., 2009; Nagalakshmi
et al., 2010), as it can be used with non-model organism that do not have already genome
defined; can reveal the exact location of exon/intron/gene boundaries, gene fusion and
sequence variation; identify splice variants and transcription start site; and it is accurate
for quantifying gene expression on a genome wide scale.
1.3 Long intergenic non-coding RNA
The non-coding genome regions may function as substrate for DNA-binding proteins
(Cheetham et al., 2013) and also as template for the transcription of a vast number of
non-coding RNAs (Cheetham et al., 2013; Carninci et al., 2005).
With the development of NGS technologies, a bigger number of transcriptomes have
been analyzed, thus acknowledging that a transcriptome is not only constitute by protein
coding transcripts but also by a high number of non-coding transcripts, that are being
transcript form regions that were believed to be “deserts” or even derived from a protein
coding gene. The widespread transcription of non-coding regions may be in the origin of
functional molecules (Ecker et al., 2012), making apparent that there is a need to take into
account non-coding elements when genome wide association studies are done.
Non-coding RNA (ncRNA) are associated with plenty of functions (Cech and Steitz,
2014) as regulation of gene expression at transcription, RNA processing and translation
level, protection of genomes from foreign nucleic acids and can be grouped in two major
classes, based on transcript size (Guttman et al., 2011):
• Small non-coding RNAs – smaller than 200 nucleotides (nt);
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• Long non-coding RNA (lncRNA) – bigger than 200 nt and up to 100 kb.
This 200 nt metric is a convenient cut-off value to exclude small RNAs in purification
protocols (Chen and Carmichael, 2010; Derrien et al., 2012; Shi et al., 2013).
According to their location to the nearest protein-coding gene, lncRNAs can be cat-
egorized as: exonic, intronic, overlapping or intergenic (Guttman et al., 2011; Derrien
et al., 2012) and can be found in sense/antisense orientation (Guttman et al., 2011).
Long intergenic non-coding RNAs (lincRNA) , have no overlap with coding genes
and can be transcribed from thousands of loci in mammalian genomes (Ulitsky and Bartel,
2013), however very few of the identified ones have been characterized; existing studies
that show that these are regulated during development and in response to certain signals,
existing also the possibility for being misexpressed in tumors, as reviewed by Tsai et al.
(2011).
In the last years the interest in lincRNAs has augmenting, as can be observe in Figure
1.4, where is depicted the evolution of the number of results when searching for ”lin-
cRNA” since 1976 until nowadays.
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Figure 1.4: Evolution of lincRNA results in PubMed since 1976 until nowadays. Data obtained
from www.ncbi.nlm.nih.gov/pubmed in 21st November 2014.
LincRNA identification
With the methodological advance and with the amount of data produced via NGS tech-
nologies, better collections of lincRNA are being produced with accurate genomics posi-
tions describing the transcripts; existing nowadays lincRNAs catalogued in several species
including human, mouse, zebrafish, fly, nematode and Arabidopsis, as reviewed by Ulit-
sky and Bartel (2013).
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Guttman et al. (2009) and Khalil et al. (2009), using chromatin signature of actively
transcribed genes - histone H3 trimethylation of lysine 4 in the promoter region and ly-
sine 36 along the transcribed region (H3K4me3 and H3K36m3, respectively) - which
characterizes the regions where the polimerase II transcription initiation and elongation
occurs, were able to identify about 1600 and 3300 lincRNAs in mouse and human cells,
respectively. The lincRNA identified using this approach show strong purifying selection
in their genomic loci, exonic sequences and promoter, and most of them evolutionary
conservation, therefore presenting functional capability.
Other approaches using a combination of several techniques (RNA-seq, cDNA and
chromatin marks) have been being used, with different criteria of certain impositions as
transcript size and distance from protein coding gene the consequence being the lack of
overlap between different studies lincRNA lists, as hypothesized by Ulitsky and Bartel
(2013).
LincRNA genomics
Studies suggest that gene “deserts” near transcription factor genes preferentially hold lin-
cRNA. The main causes for this being the regulation of lincRNA in cis, coregulation of
lincRNA and transcription factors or the presence of enhancer elements near transcrip-
tion factors favoring the emergence of lincRNA genes as suggested by Ulitsky and Bartel
(2013).
LincRNAs have no sequence or structure characteristic defining them, sharing fea-
tures with protein coding genes transcripts, hence are frequently transcribed by RNA
polymerase II (Guttman et al., 2011) as well as cis/trans-regulatory behaviour (Guttman
and Rinn, 2012). In human catalogues lincRNA genes have about 2-3 exons and these are
tendencially longer than exons of protein coding genes. They present chromatin modifi-
cation pattern, transcriptional regulation and splicing sites similar to the ones of protein
coding genes; most of the annotated lincRNAs being polyadenylated just like protein cod-
ing genes and some of them can even present circular isoform, as reviewd by Ulitsky and
Bartel (2013).
LincRNA expression tends to vary between tissues but have a more tissue/cell-specific
patterns (Derrien et al., 2012; Cheng et al., 2013; Ulitsky and Bartel, 2013). On aver-
age lincRNA expression is about a tenth of the median mRNA level (reviewed by Ulit-
sky2013), not being known if this is due to less efficient transcription or more efficient
degradation. Although the most studied lincRNA (Xist, Malat1 Neat1 and Miat) are found
almost exclusively in the nucleus, other lincRNA can be found in the cytoplasm.
Mechanism of action
The biological role of most lincRNA is still unknown, but several mechanisms are sug-
gested based on known cases (Figure 1.5). Ulitsky and Bartel (2013) divides lincRNA
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function in three groups:
• The ones that who’s nascent RNA is functional, having their action in cis, thus the
target of the lincRNAs is in the proximity of the lincRNA gene;
• Those who require a processed RNA but still act on cis;
• The ones independent of the transcription site – acting in trans.
Cotranscriptional regulation 
Bridging proteins and chromatin 
Nuclation of nuclear domains 
Molecular decoy 
Pairing with other RNA 
Cytoplasmic scaffold 
Nucleus Cytoplasm 
Figure 1.5: Generalized mechanisms of lincRNAs action. Image adapted from Ulitsky and Bartel
(2013).
With this technological development, lincRNAs (and all others lncRNA) have re-
ceived increased attention (Qiu et al., 2013) and are emerging as important regulatory
molecules in tumor-suppressor and oncogenic pathways (promoting matrix invasion of
cancer cells and tumor growth) , in addition to proteins and microRNAs (Huarte and
Rinn, 2010), bringing new potential biomarkers (Cheng et al., 2013) for diagnosis, prog-
nosis metastasis and prediction of therapy response.
1.4 Clear cell renal cell carcinoma
Kidney cancer or renal cell carcinoma (RCC) is a common group of chemotherapy-
resistant diseases, and one of the most lethal type of cancer in the urinary system (Zeng
et al., 2014).
Early stages of this type of carcinoma usually does not present any symptoms, but
as the tumor progresses symptoms like blood in the urine and pain or lump in the lower
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back or abdomen (American Cancer Society, 2014), among others, may appear. The
survival rate for patients suffering from metastatic RCC is less than 10% survive five
years subsequent to diagnosis (Zeng et al., 2014).
According to the American Cancer Society (American Cancer Society, 2014), surgery
continues to be the primary treatment and ablation therapy (uses cold or heat to destroy
tumor) can also be performed for patients that are not surgical candidates. This carcinoma
exhibits resistance to chemotherapy and radiation but the improvement in acknowledging
this carcinoma biology (genetics, affected molecular pathways, etc.) allowed to develop
targeted therapies that can be used to treat the metastatic disease.
Based on their genetic characteristics, histological features, clinical phenotype and
different responses to therapy, RCCs can be subdivided in several subtypes (Rosner et al.,
2010; Linehan et al., 2010; Crumley et al., 2013), one of the most common being clear
cell RCC (ccRCC) accounting for more than 80% of RCC cases (Ljungberg et al., 2010).
One characteristic ccRCC cells, as other cancer cells, is the metabolization of glucose
( in order to obtain adenosine triphosphate – ATP, used in as energy in different cell
processes) mostly via glycolysis followed by lactate production, opposed to glycolosis
followed by mitochondrial oxidative phosphorylation, in order to produce ATP; process
firstly described by Warburg-“Warburg effect”. This characteristic derives mostly due
to the inactive VHL gene (Pinthus et al., 2011).
1.4.1 ccRCC characteristics
Histologicaly (see Figure 1.6.B) ccRCC is characterized by compact nests of tumor cells
with clear cytoplasm separated by vascular tissue and genetically by deletions of chro-
mosome 3p segments, inactivation of von Hippel–Lindau (VHL) tumor suppression gene
gene by mutation and promoter hypermethylation, gain of chromosome 5q and loss of
chromosomes 8p, 9p, and 14q (Rini et al., 2009).
The VHL gene mutations were observed only in 52% of the analysed samples, which
may indicate that this mutation is not sufficient to explain this carcinoma and that more
studies are necessary in order to understand this carcinoma.
An important role of epigenetic regulation has also been suggested for ccRCC (Larkin
et al., 2012; The Cancer Genome Atlas, 2013; Rydzanicz et al., 2013). Several mutaitions
have been identified in tumor suppressor genes involved in chromatin and histone mod-
ifications in ccRCC, such as: SETD2 methyl transferase , SWI/SNF chromatin remod-
elling complex gene PBRM1, BAP1 histone deubiquitinase and KDM6A and KDM5C
demethylases, among others.
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(a) (b)
Figure 1.6: (A) Typical presentation of a kidney with ccRCC. Yellowish color in the lower left
corner due to lipid accumulation. (B) Histologic staining with hematoxylin and eosin of ccRCC
tumor cells. It is possible to observe nests of epithelial tumor cells with clear cytoplasm and a
distinct cell membrane, separated by vascular tissue. Figures adapted from Cohen (2014)
Deregulated microRNAs (small ncRNAs that regulate gene expressions) expression,
have also been associated with chemotherapeutic resistance of tumor cells, as reviewed
by Rydzanicz and colleagues (Rydzanicz et al., 2013), bringing a new opportunity for
discovery of molecular biomarkers, predict outcome and new therapy targets.
Glucose metabolism
VHL is part of the E3-ubiquitin ligase complex that binds to the hypoxia-inducible factor
subunit α (HIF-α) under normal oxygen concentration conditions and directs it to pro-
teosomal degradation.
Hence VHL is inactive in ccRCC, even under normal oxygen concentrations, HIF-α
is stable, thus it translocates into the nucleus, dimerizing with (HIF-β) to generate HIF-1.
Increased levels of HIF-1 results in the upregulation of genes with hypoxia response
element (HRE) site (Pinthus et al., 2011); many of these genes promote adaptation to
acute or chronic hypoxia, including the vascular endothelial growth factor (VEGF), which
promotes angiogenesis (Audenet et al., 2012).
HIF-1 controls glucose transporter 1 (Glu1), which encodes for a membrane trans-
porter of glucose, augmenting the influx of glucose into cancer cells. Hence the onco-
genic aerobic glycolysis if favored, glucose is converted into pyruvate that afterwards
is reduced to lactate by lactate dehydrogenase (LDH) and transported out of the cell by
monocarboxylate transporter 4 (MCT4); both LDH and MCT4 being controlled by HIF-
1. Lactate production induces several oncogenes, creates an acidic environment that
protects cancer cells from the immune system and has been shown to stimulate HIF-1-α
accumulation, thus augmenting HIF-1-regulated glycolysis (Pinthus et al., 2011).
HIF-1 also inhibits oxidative phosphorylation by upregulating pyruvate dehydro-
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genase kinase 1 (PDK-1) (Pinthus et al., 2011) that inhibits pyruvate’s dehydrogenase
catalyzing activity over pyruvate to acetyl-CoA, entry product for oxidative phosphoryla-
tion.
The increased oncogenic aerobic glycolysis is also an effect of the PI3K/Akt sig-
naling pathway (pathway in renal carcinoma) (Pinthus et al., 2011). This pathway can
induce the expression and membrane translocation of glucose transporters, increased
hexokinase expression and activity (activation of phosphofructokinase 1 that cataly-
ses the first irreversible reaction in glycolysis - phosphorylation of glucose to glucose-6
phosphate). This pathway activity also increases the activity of mammalian target of
rapamycin (mTOR) (Pinthus et al., 2011), kinase that regulates cell growth, proliferation,
motility, survival, protein synthesis, and transcription.
Although clear-cell RCC cells obtain their energy mostly from oncogenic aerobic gly-
colysis (produces 2 moles ATP per mole of glucose), rather that mitochondrial oxidative
phosphorylation (produces 36 moles of ATP per mole of glucose), the rate of oncogenic
aerobic glycolysis is sufficient to support the rapid and unrestricted proliferation (Pinthus
et al., 2011).
Pentose phosphate pathway
ccRCC cells also present an increased activity of the pentose phosphate pathway (PPP),
in which nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate
(R5P) are produced (Pinthus et al., 2011).
Via PPP, glucose is converted into ribulose, generating reducing agent NADPH, which
is critical for defense against oxidative stress, lipid synthesis and other anabolic reac-
tions, factors that enable ccRCC cells to have higher resistance to apoptosis, oxidative
stress and radiations, when compared with normal cells (Pinthus et al., 2011).
Lipid metabolism
Lipid metabolism is an important process in cancer cells; due to rapid cell proliferation
there a need for phospholipids and cholesterol to constitute the new cells cell membrane.
In ccRCC, the histological clear cell appearance when stained is due to a high cytoplas-
mic accumulation of lipids (Rezende et al., 1999) being suggested that this accumulation
occurs in order to exhaust the NADPH produced via PPP (Pinthus et al., 2011).
1.4.2 Therapies used in ccRCC
The use of immunotherapy using cytokines (IFN-α and IL-2 therapies) for metastatic
RCC, implies usage of high doses, associated with toxicities, fact that limited their use
(Jonasch et al., 2012).
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Three main targets are used as molecular targets for ccRCC treatment: PI3K/Akt
signaling pathway, mTOR and VEGF, as can be observed in Figure 1.7. With an inac-
tivated VHL gene,there is a stabilization and accumulation of HIF transcription factors.
This accumulation can also result via PI3K/Akt signalling pathway, hence with an in-
creased activity of mTOR, p70S6 kinase (p70S6K) is activated, enhancing the translation
of certain proteins, including HIF (Audenet et al., 2012). Stable HIF protein, translocates
into the nucleus enabaling the transcripton of hipoxia inducible genes as well as VEGF
and platelet-derived growth factor (PDGF) leading to cell migration, proliferation, and
permeability.
Figure 1.7: Molecular targets of treatments for ccRCC. Inhibition of the kinase activity of mTOR
complex 1 (mTORC1) using Temsirolimus that binds to FK506-binding protein. Bevacizumab is
ligand-binding antibody to VEGF (inhibiting its binding and activation of the receptor) and Suni-
tinib and Sorafenib are molecule that can inhibit VEGF receptor and PDGF receptor (PDGRF).
PTEN is phosphatase and tensin homologue that inhibits PI3K/Akt signaling pathway . Pro is a
proline residue. Image adapted from Audenet et al. 2012.
As reviewed by Rydzanicz et al. (2013), the use of this this targeted therapy has shown
to be more effective and less toxic than immunotherapy but the cost of the drugs are quite
elevated, present significant side effects and have relatively low response rates, still being
necessary to study in more detail ccRCC’s molecular characteristics in order to enable
a personalized treatment for each patient, taking into account all the patient and tumor
characteristics.
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1.5 Objectives
Despite the amount of studies made and the amount of identified mutations it is still not
possible to comprehend this subtype of renal carcinoma, hence we decided to explore the
lincRNA expression in ccRCC.
This work contemplates to describe how many and which lincRNA are differentially
expressed and their correlation with protein coding genes involved in ccRCC cancer.
Specifically, this work aims to:
1. Assemble the ccRCC transcriptome as base for potentially new lincRNA discovery.
2. Analysing differential lincRNA expression to characterize ccRCC.
3. LincRNA correlation with protein coding genes.
In order to achieve this objectives, a human lincRNA catalogue, with lincRNA an-
notations from several databases has to be constructed in the interest of having a more
complete tool/resource resource for assessing lincRNA expression.
Lastly, but not less important, this work focuses in the computational analysis RNA-
seq pair-end data of 62 matched normal/tumor ccRCC samples, in order to unravel the
lincRNA profile in ccRCC and quantify difference in gene expression when comparing
the normal versus the tumor samples.
Chapter 2
Human LincRNA catalog
The method and results presented in this chapter are representative of the collaborative
work with Joana Tavares.
2.1 Introduction
To uncover the lincRNA gene profile in ccRCC it is important to use a big compendium
of lincRNA annotations. To create this compendium, several databases that contain in-
formation about lincRNAs need to converge into a unique annotation that is the most
complete and has no redundancies; creating thus a new unified annotation of all lincRNA
genes across databases. Hence the ultimate goal is to identify which gene and not which
gene isoform may or may not vary, all gene isoforms when existing, were merged and if
the same gene exist across several databases, the final version of the gene is obtained by
merging all of them into one transcript that covers all gene and exons boundaries across
the databases.
2.2 Method
The software used in order to construct the annotation includes R 3.0.0 and Bedtools
2.19.0. The lincRNA list annotation was obtained by combining available data from En-
semble Gene 74, Vega 54, Gencode 19, (Volders et al., 2013), Lncipedia 2.1 (Xie et al.,
2014), UCSC (downloaded on 19th February 2014), Broad Institute’s LincRNA cata-
log (Cabili et al., 2011) - downloaded on 19th February 2014; and Zhipeng et Adelson
supplementary table S1 information for human data (Qu and Adelson, 2012).
Three crucial steps are necessary to obtain this unified list and these are: (1) filter-
ing for lincRNA transcripts, (2) merging different gene isoforms and (3) combining the
information present in all different databases (as observed in Figure 2.1). This steps are
further described in the following subsections of this Method section.
All downloaded data and the final list are converted into standard format files for exons
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and transcripts - .gtf and .bed. To ensure that there are no mistakes in the files, all files
were uploaded into UCSC Genome Browser.
2.2.1 LincRNA obtainment
After downloading the information from the databases, in order to have only lincRNA, it
is necessary to filter for:
• Non-coding transcripts;
• Transcripts longer than 200 nucleotides;
• When available, transcripts that are intergenic.
In the case of the information retrieved from UCSC and Lncipedia, the filtering pro-
cess only allows to obtain lncRNA, being necessary to subtract the Ensembl coding gene
information in order to obtain the lincRNAs. All the other lincRNA obtained from the
remaining databases will suffer the same process, and to ensure that there is no over-
lap independently of strand, hence the available RNA-seq data is not strand specific, this
subtraction will be independent of strand information.
This subtraction of the coding genes, is achieved by using the Bed tool subtractBed,
with the option -A being used in order to remove a transcript even if it is overlapped with
a coding gene by a base pair.
2.2.2 Isoform merge
When existing several isoforms for the same gene and if these are overlapped, after this
second step there will be only one isoform for a each gene.
This part of the process takes advantage of the Bed tool mergeBed with -s option
in order to take into account gene orientation, as well as -nms to retrieve the names of
the merged isoforms, further .bed/.gtf file construction. To ensure that only the isoforms
belonging to the same gene were going to be merged, a R script was integrated with
mergedBed tool. For Zhipeng et Adelson data was used only the mergedBed tool with the
above specifications, hence all the transcripts were considered as unique genes.
2.2.3 All databases merge
Finally, when merging all lincRNA information from all databases, it is necessary to
concatenate all .gtf files that resulted from the previous step, and use mergeBed tool,
using again -s and -nms options as well as -d -8 in order to ensure that the merged exons
have an overlap of at least 8 base pairs. After obtaining the merge result it is necessary to
correct the names of the exons, in order to ensure the correct construction of the resulting
transcript and to achieve that a R script was used.
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Get LincRNA transcripts 
in each database 
Merge LincRNA isoforms 
in each database 
 Merge all databases 
Figure 2.1: Process followed in order to obtain a unified LincRNA annotation accros several
databased. This process is composed by three steps that include the obtainment of LincRNA tran-
scripts from all the databases, merging isoforms for all lincRNA genes and lastly the combination
of all different databases. Dotted arrows lines - original type of information retrieved from the
database and the solid lines the different processes that the original information suffered.
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2.3 Results and discussion
2.3.1 LincRNA obtainment
After downloading the available information several steps were needed in order to obtain
only lincRNA information. The criteria, in order to filter what was or not lincRNA, were:
• Transcript must be non-coding - ncRNA;
• Transcript bigger than 200 nucleotides -lncRNA;
• Be intergenic (no overlap with coding genes) - lincRNA.
The data available from Zhipeng et Adelson publication had no gene information, fact
that obligate consider all transcripts as individual genes.
To ensure that all lincRNA genes in the annotation were intergenic, independently of
their orientation (hence the RNA-seq dataset is not strand specific) all Ensembl coding
genes were subtracted. In Figure 2.2 is possible to observe the number of genes lost
during subtraction and the associated gene lost percentage, as well as the number of genes
after.
Figure 2.2: Subtracted lnc/lincRNA that are overlapping coding genes, independently of strand.
An interesting and expected tendency during this subtraction is the lost gene percent-
age of databases that after filtering had lncRNA was similar ( around 20%) whereas the
lost gene percentage of databases that already contain only lincRNA was equal or below
10%. After this step it was possible to evaluate each database in concordance to their lin-
cRNA content and it was possible to observe that the database with more lincRNA genes/
transcripts is Noncode (as observed in Figure 2.3.A) and the database with more isoforms
per gene is Lncipedia (as observed in Figure 2.3.B). This last figure also allows to see that
for all databases more than 70% of genes have only one isoform and most of databases
have in average 3 exons per transcript (Figure 2.3.C ), similar with what is described in
literature (Cabili et al., 2011; Derrien et al., 2012; Ulitsky and Bartel, 2013).
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Figure 2.3: LincRNA information available in databases.(A) Number of transcripts and genes in
each database. The database with more genes transcripts is Noncode whereas the one with least
is UCSC. (B) Information about how many genes (in percentage) have one or more isoforms.
The database with less gene percentage of genes with more than one isoform (excluding Zhipeng
et Adelson hence all transcripts are considered as unique genes) is UCSC, whereas the one with
most gene percentage of genes with more than one isoform is Lncipedia. (C) Number of exons per
transcript in each database (in percentage) as well as associated average of exons per transcript.
2.3.2 Isoform merge
Hence the percentage of genes with one isoform is quite high (over 70%) in all databases
and the main goal is to identify which lincRNA is up/down regulated in ccRCC, and not
which isoform in specific, the isoforms merging in each database was a natural approach
to follow.
A good example of what happens during this isoform merge follows (Figure 2.4.a).
Here we can see a gene from Noncode database that initially (black representation) has
about 30 different isoforms and the result after the merge has only one isoform (blue
representation).
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Figure 2.4: (a) Visual example of what happens during isoform merge. About different isoforms
belonging to the same gene - represented in black; after isoform merge are represented by a unique
transcript - represented in blue.(b) Number of LincRNA transcripts before and after isoform merg-
ing. Number of transcripts after isoform merge is similar to number of genes as expected.
Due to the script construction only isoforms that belong to the same gene and that are
overlapped are merged, fact that implies that the gene number remains the same before
and after the merge, with the exception of the Zhipeng and Adelson data. Exceptions
also exist; due to presence of genes that have isoforms in different chromosomes (mainly
in UCSC database) or that are in the same chromosome but at a substantial distance be-
tween (isoforms separated by 200kb for example) them and in this cases, where there is
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no overlap between the isoforms no merging occurs, the gene continues to present this
characteristic even after this isoform merging process. In Figure 2.4.b) it is possible to
observe that the number of transcripts after merge is more similar to the number of genes,
and the discrepancies that exists are due to the already approached exceptions.
2.3.3 All databases merge
The merge of all databases makes possible to obtain a unified version of a gene and also
to construct the compendium of all lincRNA across several databases. In Figure 2.5.a is
possible to observe that the same gene has different versions in different databases (repre-
sented in blue) and after the final merge there is a unique version of the gene (represented
in purple).
When using this approach, what actually happens in order to construct the final gene,
all exons from all different databases are merged as specified and afterwards, in order do
consider several transcripts as belonging to the same gene, at least one exon of a transcript
from one database needs to overlap an exon from a different database.
The most important fact about this last approach is that we actually gain about 12,000
lincRNA genes when compared to Noncode, database with most genes defined as lincR-
NAs (Figure 2.5.b).
This exon overlap created an unexpected case, where two separated genes from one
database (with the same orientation), due to the presence of a gene in another database
that overlaps exons of both genes, creates a new transcript that is the combination of
these three different genes (as observed in Figure 2.5.c). This happens for 1.56% of all
transcripts present in this final merge.
For this 1.56% cases and even for all the genes annotated in all databases, in order
to assure that the gene structure is correct, transcription data for different tissues and
developmental stages, should be integrated with known annotations in order to achieve an
optimal definition of each gene.
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Figure 2.5: (a) Visual example of what happens during all databases merge. Results from isoform
merging of the same gene in different databases - blue, and the result after all databases merge -
purple.(b) Number of genes/transcripts across all databases and when combining all together. (c)
Wrong merge example. This happens for 1.56% of all transcripts present in the final merge.
This final merge also allowed to observe in intersection (Figure 2.6) between all
databases and in is noticeable that there is a lot of redundancy between them; fact that ac-
centuates the need for a database or an entity that can integrate and regulate, in this case,
the lincRNA annotation. Another thing that this figure allows to understand is which
databases contributes more with unique genes; here we can see that beyond Noncode
(database with more genes), Zhipeng and Adelson data and Lncipedia are the ones that
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allowed to increase the gene number in the final merge.
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Figure 2.6: Comparison of lincRNA annotations databases
For further analysis along this thesis, this final merged annotation will be used as
lincRNAs annotation, being this annotation a unified catalogue of all human lincRNA
present across several databases, with a total of 38134 lincRNA genes.

Chapter 3
LincRNA profile in clear cell renal cell
carcinoma
3.1 Introduction
3.1.1 Regulatory roles of lincRNA in cancer
Despite the huge efforts of lincRNAs identification, very few of them have been char-
acterized. Several studies show that they are highly regulated during development and
in response to signalling and nonetheless can be misexpressed in tumors and leukemias
(Table 3.1), as reviewed by (Tsai et al., 2011). The fact that licRNAs can control gene ex-
pression and be associated with cancer progression, suggests that their missregulation is
not an secondary effect of the cancer; hence the importance in profiling their expression.
Table 3.1: LincRANs associated with cancer. Adapted from Cheetham et al. (2013); Cheng et al.
(2013); Huarte and Rinn (2010)
LincRNA name Cancer type Molecular mechanism
Over expressed
ANRIL Prostate, leukemia Transcription regulation
HOTAIR Breast, colon, esophagus, liver, larynx, pancreas
Interaction with PRC2 and LSD1 complexes
and targeting to repressed genes
H19 Bladder Transcription regulation
HULC Hepatocellular microRNA decoy
MALAT1 Non-small-cell lung carcinoma
RNA splicing, small RNA production,
protein interaction
PCA3 Prostate Not known
PCGEM-1 Prostate RNA–protein binding transcription
PVT1 Medeolablastoma multiple myeloma cMYC-PVT1 fusion protein
Down regulated
GAS5 Breast, prostate Decoy of glucorticoid receptor
MEG3 Prostate and others Not known
PTENP1 Prostate microRNA decoy
XIST Breast, ovarian and cervical cancer Chromatin remodelling
LincRNAs can function through several types of mechanisms, in cis or in trans, some
25
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of them implying a gene expression control by recruiting histone modification enzymes
- for example overexpression of HOTAIR, that targets polycomb repressive complex 2,
altering histone H3 lysine 27 methylation and gene expression patterns, resulting in an
augmented cancer invasiveness; or by regulating alternative splicing - MALAT1, as
reviewed by Tsai et al. (2011). In Figure 3.1 is possible to observe some of the lincRNA
associated mechanisms and some of the associate lincRNAs that use those mechanisms.
Figure 3.1: LincRNAs associated mechanisms of action and lincRNAs associated with cancer that
use that kind of mechanism. Image adapted from Cheetham et al. (2013)
3.1.2 Diagnostic and potential therapeutics of lincRNAs in cancer
LincRNA are emerging as good potential new biomarkers to characterize cancer recur-
rence, progression and response to therapy (Cheng et al., 2013), hence using only one
molecule to infer this type data on a disease is much easier than profiling multiple of
other RNA molecules (Tsai et al., 2011). One good example is HOTAIR lincRNA, that
can serve as a good independent predictor of eventual metastasis and death (Tsai et al.,
2011).
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3.2 Methods
3.2.1 Data set
The RNA-seq dataset used consists of 62 matched normal/tumor tissue pairs from ccRCC
patients retrieved from The Cancer Genome Atlas (TCGA) Data Portal (//tcga-data.nci.nih.gov).
The list with the patient/sample ID for matched normal/tumor samples is available in the
appendix Table A.1.1. In Table 3.2 it is possible to observe some of the key clinical
characteristics of the patients.
Table 3.2: Characteristics of the 62 ccRCC patients whose samples were retrieved from TCGA.
The neoplasm histologic grade is relative to cell reversion of differentiation, where G2 is moder-
ately differentiated, G3 is poorly differentiated and G4 is undifferentiated.
Characteristics # of patients
Male 44Gender
Female 18
<50 8
50-60 16
60-70 22
Age at initial diagnosis
>=70 16
Alive 40Vital status
Deceased 22
I 20
II 9
III 14
Stage
IV 19
G2 25
G3 25Neoplasm histologic grade
G4 12
A3 : International Genomics Consortium 2
B0 : University of Pittsburgh 13
B2 : Christiana Healthcare 1
B8 : UNC 5
CJ : MD Anderson Cancer Center 7
CW : Mayo Clinic - Rochester 9
Tissue source site
CZ : Harvard 25
The original 124 .bam files, used to store pair-end sequence data for all samples, both
aligned as well as unaligned reads, were realigned using tophat (Trapnell et al., 2012)
tool. To realign the reads for all the samples, firstly, each original .bam file was converted
into two .fastq file (format that stores biological sequence of each sequenced read and its
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associated per base associated quality score (Cock et al., 2010)) – one per each pair-end,
using bam2fastq tool (gsl.hudsonalpha.org/information/software/bam2fastq ). These two
files are consequentially used in the tophat alignment, using as reference genome the
Ensemble human genome (GRCh37) and the expected (mean) inner distance between
mate pairs defined as 150bp. A command example for the realignamet follows:
tophat –r 150 EnsemblIndexGenome fastqFile1 fastqFile2
3.2.2 Transcriptome composition
In order to asses the transcriptome composition of ccRCC samples, (1) is necessary create
a transcriptome assembly for each alignment obtained from tophat (accepted.hists.bam
file) using LincRNA annotation combined with Ensemble gene annotation; (2) merge all
124 assemblies and finally (3) compare the merge result with all Ensembl genes and the
LincRNA annotation.
The following commands of Cufflinks version 2.2.0 were used in order to asses the
transcriptome composition:
Table 3.3: Commands used for transcriptome composition assessment
0. Combine annotation between Ensemble genes and LincRNA annotation
cuffcompare EnsembleGenes.gtf LincAnnotation.gtf Use cuffcom.combined.gtf as LincAllEnsemblCombined.gtfUse resulting .gtf as annotation for transcriptome assembly
1. Assemble transcriptome for each .gtf file
cufflinks -r LincAllEnsemblCombined .gtf -s genome.fa accepted.hits.bam
-r Annotation file
-s Genome fasta files
2. Merge all transcriptomes
cuffmerge allGtfPathResultedFromCufflinks.txt Resulting merged.gtf is the file with allccRCC sample gene composition
3. Compare known annotation of human genome with transcriptome composition
cuffcompare -r LincAllEnsemblCombined.gtf merged.gtf
-r Annotation
Use cuffcomp.combined.gtf exons with class “=” in order to
asses transcriptome composition for known genes
New lincRNA discovery
In order to find new lincRNA all exons/transcripts defined as “unknown, intergenic” (class
”u”) in the file resulting from the above cuffcompare command are considered as possi-
ble new lincRNA.
In order to asses if these are long non-coding RNA, Noncode functionality iLncRNA
(Xie et al., 2014) was used. Briefly, iLincRNA (1) removes transcripts smaller than 200 nt;
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the remaining transcripts are filtered by comparison to (2) Ensembl pesudogens and by the
(3) coding potential calculation. The remaining transcripts are considered as potentialy
new lincRNAs.
The nomenclature used to name the gene/transcript id is the one resulting from cuf-
flinks, ”XLOC” plus the ”PtNL-”(Potentially New LincRNA) prefix in order to distin-
guish from possible genes/transcrips from Broad Institute database that have the same
”XLOC” nomenclature.
3.2.3 Gene expression
In order to asses gene expression analysis, an annotation file (.gtf file) with Ensembl
protein-coding genes, LincRNA annotation and the resulting potentially new lincRNA
from Noncode was created, using cuffcompare command from Cufflinks version 2.2.0 .
Gene expression quantification (fragments per kilobase of exon per million fragments
-FPKM ) for each gene present in the combined annotation and the gene differential ex-
pression, were obtained with cuffdiff test using all 62 normal samples against all 62 tumor
samples.
FPKM analysis
All FPKM analysis was conducted in R Studio with R version 3.1.0.
From resulting file ”genes.READ GROUP TRACKING”, were obtained the FPKM
values for all genes present in the combined .gtf file containing all Ensemble protein-
coding genes, licnRNAs and potentially new lincRNA, accros all 124 samples.
Using R, all genes with variation equal to zero were removed from the analysis and,
before log2 transformation of the data, all zero FPKM values were substituted with 6.8E-8
in order not to remain with minus infinite values.
Uncovering the FPKM distribution for protein-coding, lincRNA and potentially new
lincRNA genes was the first step in understanding how this different genes behaving in
the ccRCC transcriptome.
In order to evaluate if it is possible to separate the samples into groups based on gene
expression (FPKM values), an unbiased hierarchical clustering of the first 2000 genes,
with more variation across all samples, using the Ward’s method and principal component
analysis (PCA) with all genes expression along all samples were assessed.
To represent the expression of the 2000 genes that most vary, was used a heatmap
with green, black and red colors representation; where green is low expressed and red is
highly expressed. In order to determine when one color starts and ends color brakes were
used that take into account the minimum FPKM value, 25 percentile 75 percentile and the
maximum FPKM value.
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Differentially expressed genes
From resulting file ”gene exp.DIFF”, were obtained the genes that are differentially ex-
pressed. The obtaind results were filtered for false discovery rate (FDR) smaller than 0.05
and the absolute value of the log2 fold change grater than 0.58(represents a fold change
of 1.5).
3.2.4 Enrichment analysis
In order to proceed the enrichment analysis analysis, differentially expressed (up or down
regulated, or a combined list of the previous ones) genes name (”OFFICIAL GENE SYMBOL”)
was used as gene list for DAVID -(http://david.abcc.ncifcrf.gov) - Functional Annotation
Tool (DAVID Bioinformatics Resources 6.7, NIAID/NIH), (Huang et al., 2009b, a) input
and further, ”Homo sapiens” was pinpointed as background.
Pathway enrichment analysis was assessed using DAVID Functional annotation tool,
only with KEGG PATHWAY option activated.
Gene ontology (GO) term enrichment analysis was assessed using DAVID functional
annotation tool, only with GO BP FAT option activated. The visualization of the en-
riched GO terms obtained from DAVID was done using on-line resource REVIGO -
http://revigo.irb.hr/ (Supek et al., 2011) in order to summarize the long list of enriched
GO terms, with Homo sapiens database for GO terms. In order to limit the number of en-
riched GO terms, only GO terms with FDR smaller than 0.05 were used in the REVIGO
analysis .
Differentially expressed genes name (”OFFICIAL GENE SYMBOL”) was used as
gene list for DAVID input and further, ”Homo sapiens” was pinpointed as background in
order to proceed the analysis.
3.2.5 Weighted gene correlation network analysis
A weighted gene co-expression network analysis is a method used in systems biology in
order to describe correlation patterns between genes across several samples/experiments.
Weighted gene correlation network analysis (WGCNA) is available through the R soft-
ware package WGCNA (Langfelder and Horvath, 2008) that can be used to find clusters of
highly correlated genes and relate them to external traits, among other capabilities. Hence
it takes into account the relationship among transcripts expression in a global way it can
devolve a far richer set of information than just a list of differentially expressed genes.
This approach has been successfully used in order to identify candidate biomarkers or
therapeutic targets.
A typical WGCNA analysis includes:
• Construction of a gene co-expression network with thousand of genes, that takes
into account the interactions patterns between them, being the correlation used as a
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measure of co-expression. The resulting matrix that holds the pair-wise correlation
between all genes is also called as adjacency matrix;
• Define clusters of highly correlated genes - modules, using hierarchical clustering
and Dynamic Tree Cut as tools;
• Relate modules to external information as clinical data, SNPs, proteomics, etc. in
order to find biologically interesting modules;
• Studying the relationship between modules;
• Find the key diver genes in the modules with interest. in order to identify candidate
biomarkers.
For the weighted gene co-expression network analysis, the R package WGCNA ver-
sion 1.41-1 was used, taking advantage of the existing tutorials present on Coexpression-
Network/Rpackages/WGCNA/Tutorials page.
Data preparation for network construction
Hence the data is the result from RNA-seq, the author advises a log2(FPKM+1) transfor-
mation in order to not remain with minus infinite values. All 124 samples were used in
the construction of the same network. Firstly, sample outliers were removed separately
from normal and tumor samples, using WGCNA flashClust function to hierarchically
clustering the samples based on their expression using the ”average” method and the
cutreeStatic function to cut the cluster dendogram with minimum number of object on
a branch equal to 10, being the cutoff values 160 and 180 respectively. This permit to
remove two normal (TCGA-CW-5591-11 and TCGA-B8-5552-11) and three tumor sam-
ples (TCGA-CJ-5681-01, TCGA-CZ-5989-01 and TCGA-B8-4619-01), remaining with
total of 119 samples.
These 119 samples were further used in order to remove gene with too many 0 FPKM
values along the samples or no variance, remaining with a total of 50852 genes, using for
that the goodSamplesGenes function.
In order to facilitate the computational analysis, from the 50852 remaining genes, only
the first 45000 with more variation were used.
Network construction
Before network construction is necessary to chose a ”soft power” in order to emphasize
high correlation values at the expense of low values, using the WGCNA pickSoftThreshold
function; the best power for the present data being 2.
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The network was constructed using WGCNA blockwiseModules function with Spear-
man correlation, to take advantage of its rank classification, since the lincRNA gene ex-
pression is significantly lower than the protein-coding genes one, in order to find some
correlation between these ones expression. The network type is ”signed” which means
that the adjacency is calculated as follows:
adjaceny = (0.5× (1 + correlation))softpower
Other parameters used are involved with the modules size definition and this were
defined as followed: minimum block size equal to 45000, minimum module size equal to
10, reassign threshold equal to 0, merge cut height equal to 0.25 and deep split equal to 0.
For more information on these specifications, method details should be consulted.
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3.3 Results and discussion
3.3.1 Transcriptome composition
After merging all assembled transcriptomes for the 62 matched normal/tumor samples and
comparing them to the Ensembl gene annotation combined with the LincRNAs annotation
it was possible to observe the proportion of protein-coding and lincRNA as well to find
potentially new lincRNA. In Figure 3.2 it is possible to observe the proprotion of each one
of them in the ccRCC transcriptome, with a clear and unexpected prevalence of lincRNA
(about 50% of the transcriptome is composed by lincRNA’s).
Figure 3.2: Transcriptome composition.
When we take a clear look at what happens in terms of numbers(Table 3.4) becomes
clear that although in terms of number of genes, lincRNAs have a higher proportion when
we look at the transcripts numbers, protein-coding genes clearly dominate this part, in
part, consequence of the form the lincRNA annotation was constructed.
Protein-coding genes LincRNA Potentialy new lincRNA
# genes 17282 33658 5549
# transcripts 56846 33816 5912
# exons 399228 79608 7337
Table 3.4: Trasncriptome composition in terms of the number of protein-coding, lincRNA and
potentially new lincRNA genes/transcripts/exons.
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3.3.2 Gene expression
Gene expression is evaluated taking into account FPKM values. After their normalization
it is possible to observe (Figure 3.3) and better compare the different gene expressions
between protein-coding, lincRNAs and potentially new lincRNA genes. When loking
at the FPKM values distribution and density, it becomes clear that, although the bigger
lincRNAs gene content in the transcriptome, their expression lever is clearly inferior, as
reviewed by Ulitsky and Bartel (2013).
The FPKM values distribution and density of potentially new LincRNA is slightly
different - higher 75 percentile, lower density of FPKM values close to 0 ( log2(FPKM)
close to -23) and higher density of FPKM values close to those similar to protein-coding
gene expression - when compared to already known lincRNA. This fact is due to the
method used in order to discover them - the construction of ccRCC transcriptome and
their expression along the samples in order to be defined as ”potentially new/unknown”
by the Cufflinks tool. Other hypothesis may be that these are be more specific and related
with kidney tissue/ccRCC, as hypothesized by Derrien et al. (2012), when saying that
lincRNA expression pattern is more tissue/cell-specific.
Coding LincRNA Potentially new lincRNA 
Density Density Density 
Figure 3.3: FPKM distribution along all samples and all genes with variation bigger than zero,
taking into account if genes are protein-coding, lincRNA or potentially new lincRNA.
An unbiased clustering of the FPKM values enables to separate normal samples from
tumor samples, as observed in Figures 3.4 (a),(b) and (c).
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Figure 3.4: FPKM unbiased clustering analysis. Each column is representative of one of the
following groups of analysis: protein-coding, lincRNAs and potentially new lincRNAs genes.
Each row shows the analysis results. Figures (a), (b) and (c) show the heatmap of the first 2000
genes with more expression variation in each group. The subsequent 2 rows are respective to the
PCA analysis using all genes which expression present a variation above 0. (d), (e) and (f) show
the separation of the samples using first against the second PCA component; (g), (h) and (i) the
second against the third component.
Here we have a clear separation of normal and tumor sample using either one of
protein-coding, lincRNA and potentially new lincRNA groups using just the 2000 genes
with most variation across all samples. Clear expression patterns can also be observed.
When using all genes with variation superior to zero in the principal component analysis
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(Figure 3.4 (d),(e),(f),(g),(h),(i)) , the first three components also allow a clear separation
of this samples; the variation explained by each one of the components is shown between
brackets near each one of the components. Although seams to be a clear separation of
two groups of normal samples, when separating the samples using principal component
2 against principal component 3, no clear phenotypic characteristic distinguish this sam-
ples/patients.
Differentially expressed genes
The differential expression cuffdiff test allowed to uncover 2129 genes differentialy ex-
pressed, 1128 up and 1001 down regulated in tumor samples when compared with normal
samples expression (Figure 3.5 (a)). When looking at the proportion of different genes
groups it becomes clear that most of them (more than 80%) are protein-coding genes,
but the combined proportion of lincRNA and is still significant (less then 20%) and may
implicate a role of lincRNAs in ccRCC.
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Figure 3.5: (a) Proportion of protein-coding, lincRNA and potentially new lincRNA and associ-
ated number of up and down regulated genes. (b) Heatmap of differentially expressed genes and
close up of heatmap in order to show protein-coding gene and lincRNA correlation. Row colors
in heatmap represent protein-coding genes, lincRNA and potentially new lincRNA in blue, green
and yellow respectively.
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Using this differentially expressed genes is also possible to separate most of normal
from the tumor samples 3.5 (b)), being also possible to observe that there is a correlation
between lincRNA expression and protein-coding genes ( close-up heatmap).
One lincRNA already associated with cancer is differentially expressed, up regulated -
PVT1. The expression of other lincRNAs associated with cancer (per example HOTAIR,
PCGEM1, MALAT1, ANRIL, XIST,HULC, PCA3 and MEG3) were not statistically as-
sessed by Cufflinks tool due to low data. This may implicate that a different tool, that
is not as sensible to low expression FPKM values, in order to not test their differential
expression, should be used in order to evaluate lincRNAs differential expression.
When analysing the differentially expressed protein-coding genes, in terms of their
biological process/pathways enrichment, the important roles of the regulation of the re-
sponse to wounding, leukocite activation, cell adhesion, pyruvate metabolism, glucogen-
esis (Figure 3.6 (a) ,(b)) that are highly associated with ccRCC, appear clearly.
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Figure 3.6: (a) GO term enrichment of biological processes for the up and down regulated genes,
respectively, using representation adapted from REVIGO. (b) Enriched pathways - bar length is
representative of the p-value, the bigger the bar the smaller the p-value; being the limits 9.65E-
9 ≤ p-value <= 0.005. Red color, in this representations, represent up-regulated, green down
regulated biological processes/pathways, when this type of analysis is made separately for up and
down regulated protein-coding genes; grey color represents enriched GO terms/pathways that only
appear when the combined analysis of up and down regulated protein-coding genes.
When looking separately at the up and down regulated genes it becomes clear that up
regulated protein-coding genes GO term enrichment are related with immune response,
regulation of cell proliferation and regulation of programmed cell death among others, re-
sponse to wounding, biological adhesion and transnational elongation in ccRCC; whereas
the down regulated ones are mostly associated with the carboxilic acid catabolism, oxidation-
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reduction processes and fatty acid metabolism, coenzime metabolism and cellular amide
metabolism among others.
In terms of enriched pathways, the up regulated protein-coding genes are part of up
regulated pathways like cytokine-cytokine receptor interaction, complement and coagula-
tion cascades, cell adhesion molecules (CAMs) ,natural killer cell mediated cytotoxicity,
p53 signalling pathway and Jak-STAT signalling pathway, whereas the down regulated
protein-coding genes of pathways like citrate cycle (TCA cycle), fatty acid metabolism,
glycolysis / gluconeogenesis; pathways already associated with ccRCC (Zeng et al., 2014).
Only GO terms with false discovery rate (FDR) inferior to 0.05 were used to obtain
the simplified representation of enriched terms in Figure 3.5 (b). The boxes represent
clusters of related GO terms and the size of the box reflects their p-value, the smaller the
p-value, the bigger the box.
3.3.3 Weighted gene correlation network analysis
In order to proceed with an analysis that takes into account the relationship between the
transcripts, independently of their differential expression, a weighted gene correlation net-
work analysis through WGCNA package for R (Langfelder and Horvath, 2008) followed.
This type of analysis allows, through gene profile correlations and associations with
specific traits, to find key genes for certain conditions, in this case ccRCC.
In the construction of the correlation network, a signed network was constructed in
order to keep track of the correlation type between gene expression profiles and the use
of the Spearman correlation in order to minimize the expression differences between lin-
cRNA/potentially new lincRNA and protein-coding genes, since in this type of correlation
the data is firstly ranked and then correlated, instead of using the Pearson linear correla-
tion, where the values are correlated as are presented.
The traits that will be taken into account for further analysis are: sample type (normal
or tumor samples); pathologic stage (tumor stage of different patients - stage I, II, III and
IV); patient vital status; Setd2 mutation and expression hence its association to ccRCC
and lastly but not less important, Rab38 oncogene up regulated expression (due to a read-
through chimera related with SETD2 depletion - unpublished results from our group) and
VHL gene down regulated expression in tumor samples, VHL being the gene that is the
main catalyst in ccRCC occurrence ( Figure 3.7 (a)).
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(a)
(b) (c)
Figure 3.7: WGCNA network construction. (a) Sample dendogram and traits heatmap, with a
hierarquical clustering of the samples based on the gene expression. For the heatmap interpreta-
tion, followa the color code explication: Sample type - green for normal samples, grey for tumor
samples; Pathologic stage - clear tone of blue for tumor in stage I, darkest tone of blue for stage
IV, intermediates tones for stage II and III; Vital status - white for alive, black for deceased; Setd2
mutation - clear yellow for not mutated, yellow for mutated; Setd2, Rab38 and VHL expression
- white for lower, red for high relative expression. (b) Gene dendogram and modules defined in
the correlation network. (c) Hetmap of genes, present in the network defined modules, adjacency.
Red color represents high positive adjacency; white values high negative correlation.
The module detection is based on hierarchical clustering of the expression data and
allows to define clusters of highly interconnected genes, in the case of the signed network,
genes that are positively correlated ( Figure 3.7 (b)). The grey module color represent s
genes that have no module assigned, whereas the others represent defined modules, in
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this case six modules were assigned, being the turquoise and blue modules the ones with
more genes. In Figure 3.7 (c) it is possible to observe the form that modules, and genes
inside modules correlate with other genes from other modules; clearly observable that
genes from the same module are positively correlated (red color), whereas genes from
different modules are negatively correlated (white / yellowish color), as it happens for
genes between blue and turquoise module.
If instead of a signed network, an unsigned network would have been constructed,
no distinction could have been done between positively and negatively correlated genes,
because in this case the correlation is an absolute value, and only a high or low correlation
could exist between genes. For example if a gene expression correlation with another
gene is -0.99, in the unsigned network the adjacency would be near 1 and they would be
assigned to the same module; contrary, in the signed network they are assigned to different
modules.
Module trait relationship
The next step in the network analysis is the data reduction towards the identification of
modules highly correlated with traits. Each module has a defined ”module eigengene”
- ME - which can be considered as representative of the gene expression profiles in the
module. When the module eigengenes of the defined modules are correlated with the
traits, we obtain the modules that are more correlated to the traits, in this case, the mod-
ules that showed an absolute correlation bigger than 0.5, as well as p-value inferior to 0.5,
towards at least one of the interest traits are the interest modules to study - blue, brown
and turquoise(Figure 3.8 (a)). The genes present in the blue modules are genes that are
up regulated in the tumor samples, whereas the genes from the brown and turquoise mod-
ules represent genes that are down regulated, but not mandatory defined as differentialy
expressed by cuffdiff tool.
The protein-coding genes from the blue modules are genes are enriched in genes re-
lated with positive regulation of immune system process, defense response and cell activa-
tion; turquoise module protein-coding genes with monovalent inorganic cation transport,
excretion, cation homeostasis and acetil-CoA metabolism; lastly, brown module protein-
coding genes are related with carboxilic acid catabolism, cation transport and amine bio-
synthesis.
When looking at the proportion of protein-coding, lincRNA and potentially new lin-
cRNA (Figure 3.8 (b)) it becomes clear that plenty lincRNA/potentially new lincRNA are
correlated with protein-coding genes and plausibly have an important function in ccRCC.
Chapter 3. LincRNA profile in clear cell renal cell carcinoma 41
(a)  
−1
−0.5
0
0.5
1
Sa
mp
le 
typ
e
Pa
tho
log
ic 
sta
ge
Vi
tal
 sta
tus
Se
td2
 m
uta
tio
n
Se
td2
 ex
pre
ssi
on
Ra
b3
8 e
xp
res
sio
n
VH
L e
xp
res
sio
n
MEblue
MEbrown
MEturquoise
−0.92
(2e−64)
0.086
(0.4)
0.088
(0.3)
0.11
(0.2)
−0.52
(4e−10)
0.63
(7e−16)
−0.53
(2e−10)
0.58
(1e−12)
−0.17
(0.06)
−0.15
(0.1)
0.00042
(1)
0.45
(2e−07)
−0.35
(9e−05)
0.4
(4e−06)
0.91
(6e−60)
−0.061
(0.5)
−0.047
(0.6)
−0.06
(0.5)
0.42
(1e−06)
−0.6
(5e−14)
0.52
(4e−10)
(b)
4662 
1055 
4303 
2577 
724 
2286 
1014 322 1256 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
Potentialy 
new 
lincRNA 
LincRNA 
Coding 
Figure 3.8: WGCNA modules analysis. (a) Module-trait relationship depicting correlations and
associated Fisher asymptotic p-value between brackets for blue, turquoise and brown module, with
several traits. (b) Gene proportion and associated number of different gene groups present in the
interest modules.
In order to find interest genes in this modules and reduce the gene universe in the
modules, genes were filtered based on gene membership measure - correlation of the
gene expression pattern with the module eigengene; the ones with module membership
higher than 0.8 were further filtered based on their gene significance towards the traits,
being this gene significance the correlation between the gene expression profile and the
trait, being the absolute value of gene significance superior than 0.5.
As observable in Figure 3.8, the turquoise and blue module are highly correlated with
the sample type (absolute correlation value superior to 0.90 and small p-values). This
modules are an optimal start point in order to uncover lincRNAs in the remaining module
genes, highly associated with normal/ tumor sample. Curiously, genes already associated
with ccRCC, SETD2 and VHL, show the same type of correlation with the same modules,
whereas RAB38 has an opposite correlation with them.
If clustering the first 200 genes more correlated with sample type from blue and
turquiose module, is possible to perfectly separate the normal samples from the tumor
samples (Figure 3.9 A and B). When closing-up on the gene cluster, is possible to observe
a co-expression/correlation of protein-coding genes, involved in biological functions en-
riched in ccRCC, and lincRNAs, although the last ones have a relative expression inferior
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to the protein-coding genes.
Figure 3.9: A Heatmap of the top 200 genes more correlated with sample type (171 protein-
coding genes; 27 lincRNAs and 2 potentially new lincRNAs). B Close-up in gene clustering
in order to show co-expression/correlation between protein coding-genes and lincRNAs. Row
colors represent gene type: blue - protein-coding genes, green - lincRNA, yellow - potentially new
lincRNA.
One of the lincRNA up regulated and present in this list is PVT1; that has been already
associated with cancer. In colorectal cancer it generates antiapoptotic activity and an
abnormal expression of PVT1 was a prognostic indicator for patients with this cancer type
(Takahashi et al., 2014); by transfecting colorectal cells with PVT1-small interference
RNA, Takahashi et al. (2014) showed that the cell had a significant lost their invasion and
proliferation, with TGF-β pathway and apoptotic signals significantly activated.
PVT1 expression levels in tumor tissue were significantly higher that the ones in the
normal samples (Figure 3.10 (s)). Hence having matched normal/tumor samples, and if
looking at the PVT1 expression in normal samples (patients were divided in two groups
based on the median PVT1 expression in normal samples - if superior high else wise low
expression), ccRCC patients normal samples with high PVT-1 expression had a signifi-
cantly poorer prognosis when compared to low PVT1 expression levels.
Recent discoveries (Tseng et al., 2014) find that PVT1 can control the levels MYC (up
regulated expression levels in ccRCC - Figure 3.10 (b)) by stabilizing the MYC protein,
leading the authors believe that PVT1 interferes with MYC normal phosphorylation of
threonine 58 induced degradation stabilizing the proteinn and increasing its levels.
MYC is a cell cycle regulator whose expression is induced by HIF (Rini et al., 2009)
and it has been suggested that MYC pathway activation is essential in ccRCC develop-
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ment and progression. Several pathways related to ccRCC (metabolism, signal transduc-
tion, translation, etc.) contain genes that are MYC targets, like BCL2, CCND1, PCNA,
PGK1 and VEGFA (Rydzanicz et al., 2013); being all this genes present in the same blue
module as PVT1, as well as MYC gene itself.
(a)
l
l
l
l
l
l
0
1
2
3
PVT1 expression 
 p = 9.3e−21
Sample type
lo
g2
(F
PK
M
+1
)
Tumor Normal 0 2 4 6 8
0.0
0.2
0.4
0.6
0.8
1.0
Patients stratified by PVT1 expression 
 in normal samples
Time (Years)
Su
rv
iv
al
 p
ro
ba
bi
lit
y
Expression
Low 
High
logrank P = 0.035
(b)
Figure 3.10: (a) PVT1 lincRNA expression in tumor and normal samples and Kaplan–Meier over-
all survival curves for 60 patients with ccRCC classified according to PVT1 expression level in
normal samples. (b) MYC gene expression levels in tumor and normal samples.
This over expression of PVT1 in ccRCC combined with the literature may suggest
a putative role for PVT1 in ccRCC progression, further studies being needed as well as
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more data integration in order to ensure his plausible role in ccRCC.
With this type of overall analysis is possible to identify differentially expressed genes
(2029 differentially expressed genes in ccRCC), including protein-coding genes, lincR-
NAs as well as potentially new lincRNA (found 5549 potentially new genes). On the other
hand, using the weighted gene correlation network analysis allows to find genes highly
correlated to certain traits, for example PVT1 possible involvement in ccRCC.
Chapter 4
Final Remarks and Future Perspectives
In this work, one of the most challenging part was the part corresponding to the hu-
man lincRNA catalogue construction. Several databases have information corresponding
to lincRNA annotation, but not much consensus exist between them, fact that made us
construct a human catalogue with a unified version of all lincRNAs across them. This
catalogue allowed to achieve a final number of 38135 lincRNAs.
The different data formats in different databases, the instability of the databases that
keep changing the gene identification and available data formats, brought another level of
complications never expected before.
Due to lack of data integration, the merge of the different information present in the
databases into one unique catalogue was a struggling process in order to define the best
parameters for that to happen. This factor lead us to compromise and acknowledge our
catalogue imperfections. Thus, 1.56% of the annotations present in the catalogue derive
from the merge of two different annotated lincRNA from the same database due to an
exon overlap with an annotated lincRNA from a different database.
This kind of problem may let us think which annotation is correct... from database A
or from database B? but it actually makes me ask: ”What is in fact a gene and what defines
an exon?”. I cannot answer to that question, but I rather suggest that a gene is a portion
of DNA transcribed into RNA in a certain moment, controlled by several other factors. In
order to respond to it, to have better annotations out there, more data integration has to
occur as well a global effort for that to happen.
The second part presented in this thesis, and the main objective, was to characterize
the lincRNAs expression profile in ccRCC. The RNA-seq dataset was large, comprising
124 samples (62 tumor normal paired samples), increasing the difficulty of the project.
The first step was to create the transcriptome composition of ccRCC, using all this sam-
ples, in order to find potentially new lincRNAs. 5549 new transcripts were identified
and were here designated as potentially new lincRNAs, since the possibility of being new
pseudogenes could not be discarded. Thus, further analysis, would be needed to clearly
classify all the new transcripts.
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The second step was to asses differential gene expression, where a total of 2129 genes
were significantly altered between tumor and normal samples (including protein-coding
genes, annotated and potentially new lincRNAs). Not a very large number of lincRNAs
were found to be differentialy expressed, in part because of the statistical tool used (Cuf-
flinks). Due to their low expression levels, for many of the lincRNAs the statistical test
was not even effectuated. Thus, we believe that to study low expressed genes, such as
lincRNAs, other statistical tools (like edgeR or DESeq R packages) should be more ap-
propriate.
To complement our analysis we used a weighted gene correlation network analysis,
in order to take into account the relation between transcripts co-expression. This type
of analysis revealed very promising results, allowing to find lincRNAs highly correlated
with protein-coding genes and also associated to several cancer traits. Further data mining
with this results has to be made, integrating it with other type of available data and other
available bioinformatic tools.
In a summary, I would say that this analysis allowed to give the first steps in order
to understand the lincRNAs importance and leaves an open window into unravelling new
clues for ccRCC occurrence and aggressiveness. Further approaches, computational anal-
ysis and also laboratory experiments should be preformed to exhaustively understand the
mechanisms involved in ccRCC.
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Appendix
LincRNA profile in ccRCC
A.1.1 TCGA patient and sample ID
Table A.1.1: TCGA patients and sample ID
Patient ID Normalsample ID
Tumor
sample ID Patient ID
Normal
sample ID
Tumor
sample ID
TCGA-A3-3358 TCGA-A3-3358-11 TCGA-A3-3358-01 TCGA-CW-5587 TCGA-CW-5587-11 TCGA-CW-5587-01
TCGA-A3-3387 TCGA-A3-3387-11 TCGA-A3-3387-01 TCGA-CW-5591 TCGA-CW-5591-11 TCGA-CW-5591-01
TCGA-B0-4700 TCGA-B0-4700-11 TCGA-B0-4700-01 TCGA-CW-6087 TCGA-CW-6087-11 TCGA-CW-6087-01
TCGA-B0-4712 TCGA-B0-4712-11 TCGA-B0-4712-01 TCGA-CW-6088 TCGA-CW-6088-11 TCGA-CW-6088-01
TCGA-B0-5402 TCGA-B0-5402-11 TCGA-B0-5402-01 TCGA-CW-6090 TCGA-CW-6090-11 TCGA-CW-6090-01
TCGA-B0-5691 TCGA-B0-5691-11 TCGA-B0-5691-01 TCGA-CZ-4863 TCGA-CZ-4863-11 TCGA-CZ-4863-01
TCGA-B0-5694 TCGA-B0-5694-11 TCGA-B0-5694-01 TCGA-CZ-4864 TCGA-CZ-4864-11 TCGA-CZ-4864-01
TCGA-B0-5696 TCGA-B0-5696-11 TCGA-B0-5696-01 TCGA-CZ-4865 TCGA-CZ-4865-11 TCGA-CZ-4865-01
TCGA-B0-5697 TCGA-B0-5697-11 TCGA-B0-5697-01 TCGA-CZ-5452 TCGA-CZ-5452-11 TCGA-CZ-5452-01
TCGA-B0-5699 TCGA-B0-5699-11 TCGA-B0-5699-01 TCGA-CZ-5453 TCGA-CZ-5453-11 TCGA-CZ-5453-01
TCGA-B0-5703 TCGA-B0-5703-11 TCGA-B0-5703-01 TCGA-CZ-5454 TCGA-CZ-5454-11 TCGA-CZ-5454-01
TCGA-B0-5705 TCGA-B0-5705-11 TCGA-B0-5705-01 TCGA-CZ-5455 TCGA-CZ-5455-11 TCGA-CZ-5455-01
TCGA-B0-5709 TCGA-B0-5709-11 TCGA-B0-5709-01 TCGA-CZ-5456 TCGA-CZ-5456-11 TCGA-CZ-5456-01
TCGA-B0-5711 TCGA-B0-5711-11 TCGA-B0-5711-01 TCGA-CZ-5457 TCGA-CZ-5457-11 TCGA-CZ-5457-01
TCGA-B0-5712 TCGA-B0-5712-11 TCGA-B0-5712-01 TCGA-CZ-5458 TCGA-CZ-5458-11 TCGA-CZ-5458-01
TCGA-B2-5636 TCGA-B2-5636-11 TCGA-B2-5636-01 TCGA-CZ-5461 TCGA-CZ-5461-11 TCGA-CZ-5461-01
TCGA-B8-4619 TCGA-B8-4619-11 TCGA-B8-4619-01 TCGA-CZ-5462 TCGA-CZ-5462-11 TCGA-CZ-5462-01
TCGA-B8-4620 TCGA-B8-4620-11 TCGA-B8-4620-01 TCGA-CZ-5463 TCGA-CZ-5463-11 TCGA-CZ-5463-01
TCGA-B8-4622 TCGA-B8-4622-11 TCGA-B8-4622-01 TCGA-CZ-5465 TCGA-CZ-5465-11 TCGA-CZ-5465-01
TCGA-B8-5549 TCGA-B8-5549-11 TCGA-B8-5549-01 TCGA-CZ-5467 TCGA-CZ-5467-11 TCGA-CZ-5467-01
TCGA-B8-5552 TCGA-B8-5552-11 TCGA-B8-5552-01 TCGA-CZ-5468 TCGA-CZ-5468-11 TCGA-CZ-5468-01
TCGA-CJ-5676 TCGA-CJ-5676-11 TCGA-CJ-5676-01 TCGA-CZ-5469 TCGA-CZ-5469-11 TCGA-CZ-5469-01
TCGA-CJ-5677 TCGA-CJ-5677-11 TCGA-CJ-5677-01 TCGA-CZ-5470 TCGA-CZ-5470-11 TCGA-CZ-5470-01
TCGA-CJ-5678 TCGA-CJ-5678-11 TCGA-CJ-5678-01 TCGA-CZ-5982 TCGA-CZ-5982-11 TCGA-CZ-5982-01
TCGA-CJ-5679 TCGA-CJ-5679-11 TCGA-CJ-5679-01 TCGA-CZ-5984 TCGA-CZ-5984-11 TCGA-CZ-5984-01
TCGA-CJ-5680 TCGA-CJ-5680-11 TCGA-CJ-5680-01 TCGA-CZ-5985 TCGA-CZ-5985-11 TCGA-CZ-5985-01
TCGA-CJ-5681 TCGA-CJ-5681-11 TCGA-CJ-5681-01 TCGA-CZ-5986 TCGA-CZ-5986-11 TCGA-CZ-5986-01
TCGA-CJ-6030 TCGA-CJ-6030-11 TCGA-CJ-6030-01 TCGA-CZ-5987 TCGA-CZ-5987-11 TCGA-CZ-5987-01
TCGA-CW-5580 TCGA-CW-5580-11 TCGA-CW-5580-01 TCGA-CZ-5988 TCGA-CZ-5988-11 TCGA-CZ-5988-01
TCGA-CW-5581 TCGA-CW-5581-11 TCGA-CW-5581-01 TCGA-CZ-5989 TCGA-CZ-5989-11 TCGA-CZ-5989-01
TCGA-CW-5584 TCGA-CW-5584-11 TCGA-CW-5584-01 TCGA-CZ-5989 TCGA-CZ-5989-11 TCGA-CZ-5989-01
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